Peter Lin MD, CCFPDirector, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada
Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years. Currently, he is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He lectures and speaks international on a variety of topics and maintains a busy family practice in Toronto.
Dr. Lin was a consultant for Perspectives in Cardiology, and was on the editorial board of The Canadian Review of Alzheimer's Disease and Other Dementias. He had been the chairman of the Dementia Congress in the US for 4 years. He has also served on the editorial board of Pri-Med. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
Dr. Lin has consulted with the following companies on Continuing Medical Education programs:
Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Novartis, Pfizer, Servier, Sanofi, Abbott, Mylan, HLS Therapeutics Inc.
He also does Continuing Medical Education for the companies. No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers
- REGN-COV2 Reduces Viral Load in COVID-19 Patients
- The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine
- First-Line Drug Treatment for Hypertension According to Age and Ethnicity
- Efficacy and Safety of Lowering LDL Cholesterol in Older Patients
- Time to Benefit of Statin Therapy for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years
- Ticagrelor Added to Aspirin in Acute Ischemic Stroke or TIA in Prevention of Disabling Stroke
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes